Next Article in Journal
Functional Changes of White Matter Are Related to Human Pain Sensitivity during Sustained Nociception
Next Article in Special Issue
Optimizing Platelet-Rich Plasma: Spin Time and Sample Source
Previous Article in Journal
Assessing the Genotoxicity of Cellulose Nanomaterials in a Co-Culture of Human Lung Epithelial Cells and Monocyte-Derived Macrophages
Previous Article in Special Issue
Retrospective Analysis of Responders and Impaired Patients with Knee Osteoarthritis Treated with Two Consecutive Injections of Very Pure Platelet-Rich Plasma (PRP)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Bioengineering
Volume 10
Issue 8
10.3390/bioengineering10080987
bioengineering-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Perspective

Anti-Aging Potential of Platelet Rich Plasma (PRP): Evidence from Osteoarthritis (OA) and Applications in Senescence and Inflammaging

by
James Vun
1,2,
Neelam Iqbal
3,
Elena Jones
1 and
Payal Ganguly
1,*
1
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK
2
Leeds Orthopaedic & Trauma Sciences, Leeds General Infirmary, University of Leeds, Leeds LS97TF, UK
3
School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, UK
*
Author to whom correspondence should be addressed.
Bioengineering 2023, 10(8), 987; https://doi.org/10.3390/bioengineering10080987
Submission received: 8 June 2023 / Revised: 21 July 2023 / Accepted: 15 August 2023 / Published: 21 August 2023
(This article belongs to the Special Issue Advances in Autologous PRP Therapy)
Browse Figure
Review Reports Versions Notes

Abstract

:
Aging and age-related changes impact the quality of life (QOL) in elderly with a decline in movement, cognitive abilities and increased vulnerability towards age-related diseases (ARDs). One of the key contributing factors is cellular senescence, which is triggered majorly by DNA damage response (DDR). Accumulated senescent cells (SCs) release senescence-associated secretory phenotype (SASP), which includes pro-inflammatory cytokines, matrix metalloproteinases (MMPs), lipids and chemokines that are detrimental to the surrounding tissues. Chronic low-grade inflammation in the elderly or inflammaging is also associated with cellular senescence and contributes to ARDs. The literature from the last decade has recorded the use of platelet rich plasma (PRP) to combat senescence and inflammation, alleviate pain as an analgesic, promote tissue regeneration and repair via angiogenesis—all of which are essential in anti-aging and tissue regeneration strategies. In the last few decades, platelet-rich plasma (PRP) has been used as an anti-aging treatment option for dermatological applications and with great interest in tissue regeneration for orthopaedic applications, especially in osteoarthritis (OA). In this exploration, we connect the intricate relationship between aging, ARDs, senescence and inflammation and delve into PRP’s properties and potential benefits. We conduct a comparative review of the current literature on PRP treatment strategies, paying particular attention to the instances strongly linked to ARDs. Finally, upon careful consideration of this interconnected information in the context of aging, we suggest a prospective role for PRP in developing anti-aging therapeutic strategies.

1. Introduction

Advancing age and age-related changes have presented challenges in healthcare across the globe ranging from increased vulnerability towards diseases to reduced quality of life (QOL). According to the World Health Organisation (WHO), by the year 2030, every 1 in 6 person will be over 60, and by the year 2050, there will be over 2 billion people aged 60 and above [1]. Biologically, aging has been defined as accumulating several damages at the cellular level over time, potentially resulting in reduced physical and mental abilities. Therefore, it often results in various age-related diseases (ARDs), accelerating the natural progression towards death [2]. Since advancing age is closely associated with ARDs and global health challenges, the WHO predicts that the increasing aging population will present economic and social challenges worldwide [1].
The last three decades have witnessed an increasing number of studies investigating age-related changes at the cellular level. Re-defining the underlying causes of these changes was the 2013 article by Lopez-Otin et al. describing the nine hallmarks of aging [2]. They outlined nine factors and categorised them as primary hallmarks—that cause the damage (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis); antagonistic hallmarks—that are the responses to the caused damage (deregulated nutrient sensing, mitochondrial dysfunction and senescence); and integrative hallmarks—that eventually result in the phenotypes of aging (stem cell exhaustion, altered intercellular communication) [2]. However, since then, investigations of age-related changes have amplified due to the increased interest among researchers. More recently, the nine hallmarks of aging were updated as the ‘new hallmarks of aging’ at the 2022 Copenhagen Aging meeting [3]. The added factors included age-related inflammation—also referred to as inflammaging, compromised autophagy, altered mechanical properties, microbiome disturbance and dysregulation of RNA processing.
Several conditions and ARDs have been found to severely impact the elderly, including neurodegenerative diseases leading to cognitive impairment, hearing loss, cardiovascular complications and reduced mobility due to musculoskeletal (MSK) alterations [4]. Among these, hip and knee osteoarthritis (OA) are known to be the most significant contributors to global disability, with the likelihood of its burden being underestimated [5]. Pain, rigidity in the joints, inflammation and difficulties in movement are well-recognised symptoms of OA. Despite the continuous efforts in OA research, the usual approaches include pain management and/or invasive surgeries. At the cellular level, various factors contribute towards OA; however, advancing age, age-related inflammation and senescence have been identified as critical factors influencing the disease progression [6,7,8,9]. Senescence is the irreversible arrest of cellular growth and proliferation and contributes towards aging and age-related changes. Senescent cells (SCs) produce senescence-associated secretory phenotype (SASP) that are also closely linked to contributors of several ARDs. SASP is also known to fuel the chronic, systemic-low grade inflammation in aging, that is, ‘inflammaging’, a significant risk factor contributing towards ARDs [10].
Interestingly, there has been an increase in the use of platelet rich plasma (PRP) for treating ARDs like OA [11,12,13] in the last three decades. PRP has been described as, ‘a fraction of blood plasma containing platelets in a higher concentration than at baseline blood levels’ by Sanchez et al. [14]. Some studies have described it as a fluid with a platelet concentration of at least 1 × 106 platelets/mL in 5 mL of plasma, known to contain 3 to 5-times the growth factor concentration and associated with enhancement of healing [15,16]. Over 1100 proteins have been found in PRP, including growth factors, enzymes and messenger molecules [17]. These contribute towards processes like proliferation, differentiation, angiogenesis and matrix modelling [18,19]. The treatment approach involves injection of autologous PRP containing these potent growth factors into the patient, and is not known to have any adverse effects. The primary application for PRP-based therapy relies on the rationale that concentrated platelets injected at the injury site may initiate tissue repair via the multiple growth factors residing inside PRP [20]. The procedure has now been outlined as a guideline by the National Institute for Health and Care Excellence (NICE), UK [21], to alleviate pain and relieve symptoms in OA patients.
While several trials and investigations have investigated the effect of PRP on OA treatment [22,23], there has also been an increased interest in using PRP in other applications. These include treatment of androgenic alopecia and hair regrowth [24,25], bone and spine regeneration [26,27,28], dentistry [29] and skin regeneration [17,30]. Along with several other growth factors and proteins, PRP is also known to contain tissue inhibitors of metalloproteinase 2 (TIMP2) and growth differentiation factor 11 (GDF11) proteins that play a critical role in tissue regeneration and repair. Thus, these are also referred to as the anti-aging proteins in PRP, which have been reported to decline with advancing age and in diabetes mellitus [31].
Last year, we worked with mesenchymal stromal cells (MSCs) from OA patients before and after PRP injections. MSCs from older OA patients had a higher increase in their proliferative capacity. They also demonstrated higher protection from oxidative stress as indicated by senescence assay [32]. Reported investigations of the anti-inflammatory potential of PRP [33] and the use of PRP to combat senescence [34,35] further indicate the potential of PRP in use beyond OA in other ARDs for tissue regeneration. Considering our recently published study [32], the increase or use of PRP in OA and the current literature available outlining the impact of PRP in therapeutic applications mentioned above, we hypothesised that PRP potentially has anti-aging properties that can be further exploited for age-related changes and the treatment of several ARDs. This review delineates the current evidence to link aging, senescence, inflammaging and ARDs, with OA being our reference ARD. We then discuss the potential of PRP being applied for their anti-aging properties in aging in general as well as in several other ARDs.

2. Senescence and Inflammaging

2.1. Senescence

The term senescence was first used in 1961 and described as an irreversible loss of proliferative capacity in somatic cells [36]. Since then, we have gathered a much better understanding of the biological significance of senescence. While the mechanism of senescence is crucial for biological events like tumour suppression [37], it has increasingly been associated with tumour progression, damage accumulation, aging and several ARDs [38]. SCs are identified by the loss of their ability to proliferate, by their larger-than-normal size, by the positive stain for senescence-associated beta-galactosidase (SA-β-gal) and by higher expression of transcription factors like p16 and p53 [38,39]. It may be caused due to various factors or stressors contributing towards SCs; however, DNA damage response (DDR) remains among the most well-explored stressors for senescence [40,41,42].
Cellular senescence depletes tissues of the progenitor of stem cells, leading to one of the hallmarks of aging: stem cell exhaustion, that is, a decline in the number of stem cells [43,44]. This exhaustion eventually leads to compromised tissue repair and regeneration [45] and damage in the surrounding tissues [46,47]. Concerning OA, the impact of senescence is well acknowledged and is often used for dissecting the pathways involved in the disease progression [6,7,8,9,48,49,50]. Additionally, clearance of SCs in mice using an inhibitor of anti-apoptotic molecules (ABT263) or by using transgenic mice resulted in the rejuvenation of hematopoietic stem cells (HSCs) [51] and relieved pain and increased cartilage development [52], respectively. A similar observation was made by treating aged mice with a senolytic drug (Navitoclax), where the drug eliminated senescent cardiomyocytes, improved myocardial modelling and overall survival after myocardial infarction [53]. These observations have made senescence an interesting target for potential anti-aging therapies.
SCs produce factors known as SASP, which is how the SCs contribute towards aging and ARDs. SASP includes a mix of pro-inflammatory cytokines, chemokines, lipids, matrix-metalloproteinases (MMPs) and matrix-degrading molecules, accelerating cellular damage and advancing aging and ARDs [54,55]. The presence of the pro-inflammatory cytokine and the chemokines inhibit functions like proliferation and differentiation and cause cellular damage [38]. SASP has been found to increase with age with a dynamic and long-lasting program for SCs. Gorgulis and colleagues collated and described several factors that may be used as a guideline for senescence markers [56]. It plays a significant role in SCs that ultimately contributes towards accelerated aging and ARDs via the process of cellular senescence [57] and, as outlined earlier, also towards inflammaging [10].

2.2. Inflammaging

Inflammaging describes the upregulated inflammatory state of tissues that progresses with advancing age and has been added to the scientific dictionary only in the last two decades [58]. It is identified by an increase in the levels of several pro-inflammatory cytokines of interleukins 1, 6 (IL-1, IL-6) and tumour necrosis factor (TNF), which are all well recognised in inflammatory diseases [59,60,61]. Inflammaging is believed to result from continuous lifetime exposure to clinical and non-clinical infections and non-infectious agents causing irreversible cellular and molecular damage, which is not always clinically evident. However, its exact mechanisms are yet to be underpinned, although inflammaging is believed to share similarities in pathways with inflammation in diseased conditions [61,62].
Inflammaging has been projected to withhold significant risk towards morbidity and mortality in the health of the elderly, as it shares the inflammatory pathogenesis with a number of ARDs and other degenerative joint diseases [62,63,64]. For example, in OA, both inflammation and cellular senescence are key contributors to the disease progression. Senescent osteocytes increase in OA and also increases the receptor activator of nuclear kappa-B ligand (RANKL)-related rate of bone resorption [65,66]. The process subsequently triggers inflammation and the related stages, encompassing the continuous effort for healing. It is hypothesised that this process intensifies the severity of the condition [67,68]. Considering OA as our reference for an ARD for this article, it appears closely integrated with inflammaging, as are other ARDs [69], making inflammaging an increasingly unavoidable factor in aging and regenerative research. Thus, it is no surprise that inflammaging has, like senescence, also been hypothesised to be a potential target towards anti-aging strategies [63,70].

3. Platelet-Rich Plasma (PRP)

PRP has been used in numerous studies for its regenerative potential, especially in OA and has been discussed in great detail in other publications [12,23,32,71,72,73,74,75]. This section outlines our current knowledge of PRP and its properties that make it an attractive agent for use in these studies. We acknowledge the ambiguity in its terminology used in the literature and then focus on the current application of PRP by outlining its clinical relevance. We then summarise the results of these applications to critically assess if PRP, in reality, contributed to regenerating the tissues and disease management (Table 1, Section 4.1).

3.1. Properties and Contents of PRP and Platelet-Derived Biologics

When harvested with anticoagulants, peripheral blood can be centrifuged to produce two distinct fractions: platelet rich plasma (PRP) and platelet poor plasma (PPP). PRP, obtained from a patient’s peripheral blood, is a rich source of autologous growth factors and anti-aging proteins [31,76]. Noteworthy, not all PRP described in the literature are the same regarding physical properties and growth factor contents [20]. ‘Non-activated’ PRP is produced following peripheral blood centrifugation and delivered in liquid form. Therefore, the release of growth factors from non-activated PRP occurs in vivo through intrinsic biological activation by the host ‘on demand’. On the other hand, the release of growth factors from ‘activated’ PRP was induced ex vivo prior to administration. These were commonly induced through physical disruption, lysis or chemical activation. Physical disruption, usually through repeated freeze–thaw cycles or ultrasound sonification, results in platelet lysis and the production of acellular ‘platelet lysate (PL)’ abundant in growth factors [77]. Chemical activation with calcium salts or thrombin leads to (i) platelet degranulation and release of a plasmatic fraction full of growth factors, known more commonly as platelet releasate, a plasma rich in growth factors, or platelet release supernatants; and (ii) fibrinogenesis and the formation of a platelet-rich clot—platelet gel [78].
PRP remains loosely used in the literature as an all-encompassing term for any platelet-derived biologic. A recent systematic review highlighted the importance of accurately describing platelet-derived biologic, physical properties, formulation and contents to enable accurate comparison between studies [79]. The shortcomings of the existing PRP classification systems are highlighted by the lack of standardised protocols and definition for centrifugation and preparation, cellular components such as platelet concentration, red and white blood cell counts, and the procedure for platelet activation [80,81,82,83,84,85]. However, in 2020, Kon et al. suggested a novel coded classification system for PRP. The code includes a sequence of six digits grouped in pairs indicating parameters of platelet composition, purity, and activation: N1-N2-N3-N4-N5-N6. While it is yet to be accepted as a standardised method, it would provide essential details in a simplified manner [13]. PRP and related products have been given several names, such as leukocyte rich-PRP (LR-PRP), leukocyte poor-PRP (LP-PRP), platelet-rich fibrin (PRF) and pure-PRP (pPRP) based on the formulation prepared for the particular study. Though these terminologies are beyond the remit of this article, Everts et al. have provided an exhaustive review of the subject [20].

3.2. Current Applications of PRP

Due to its ease of harvesting, as well as being autologous and readily available, PRP has gained popularity and is clinically applied in treating acute fractures, fracture non-union, diseased or inflamed tendons (tendinopathies), OA and wound healing. A recent systematic review and meta-analysis on 10 randomised controlled trials (RCT) with 652 patients identified PRP as being able to reduce fracture healing time, enhance bone mineral density and decrease the risk of revision surgeries [86]. Nonetheless, due to the absence of randomised controlled trials (RCTs) evaluating the effectiveness of PRP in treating fracture non-union, its incorporation into the standard surgical management of fracture non-unions has not yet been realised [87].
PRP has also been used for the treatment of spinal diseases. Intradiscal injection therapy of PRP for degenerative disc disease is safe and improves pain, disability and QOL [88]. Numerous in vitro investigations of PRP in spinal diseases have been reviewed extensively by Kawabata et al., indicating that PRP can potentially be a breakthrough treatment in spine-related diseases. However, they also stated that clinical outcomes of PRP applied in spinal fusion surgery and spinal cord injury have been mixed, with studies differing in their final results [27] . Ultimately, they summarise the need for larger RCTs with careful patient selection and PRP component considerations to establish PRP as an evidence-based treatment [27]. With regards to tendon pathologies, Masiollo et al. in their recent systematic review and meta-analysis, found no significant differences in terms of pain scores and functional outcome scores when comparing the use of PRP injections against other treatments (e.g., steroid injection, local anaesthetic, MSC injection or conservative non-injective interventions) when applied in lateral epicondylitis, plantar fasciitis, achilles tendinopathy or rotator cuff tendinopathy [89].
As mentioned earlier, the application of PRP in OA has been widely studied. Studies have explored the application of PRP alone, the combinatory use of PRP with other biologics, or PRP as an adjunct to surgical procedures in the treatment of OA. A recent meta-analysis assessing six RCTs compared the use of PRP (n = 338) against hyaluronic acid (HA) (n = 323) in knee OA, concluded that PRP is superior over HA in improved Western Ontario McMaster Universities OA Index (WOMAC) and Physical Functional Scores at 12 months, while there was no difference in the International Knee Documentation Committee (IKDC) and EuroQol—visual analogue scales (EQ-VAS) Scores [90]. In their meta-analysis of six RCTs (n = 493 cases), Zhao et al. identified the combined application of PRP with MSC (PRP+MSC) to significantly reduce VAS scores at 6 and 12 months when compared against control, HA injection or PRP alone; and WOMAC scores to be more effectively reduced at 3 and 6 months following MSC+PRP treatment. Knee injury and OA outcome score (KOOS) at 12 months indicated no difference between MSC+PRP and control groups [72]. Another systematic review similarly reported on the longevity of pain relief and improvement of functional outcomes following PRP injection when compared against PPP, corticosteroids and HA [75].
The use of ‘orthobiologics’ in the treatment of OA, with PRP being one of the more popular blood-based derivatives, has been the recent focus of the European Society of Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) Orthobiologics Initiative (ORBIT) steering group [91]. The ESSKA ORBIT group drew attention to and challenged the focus of the current literature, which is often limited to reporting the pain-relieving effects and functional improvements following injectables in OA (i.e., orthobiologics such as PRP, corticosteroids, viscosupplementation such as HA). The ORBIT steering group further highlighted the importance of looking at whether PRP contains any disease-modifying effects in the pathophysiology of OA, leading to the group’s systematic review of 44 pre-clinical studies with 1251 animals. The systematic review demonstrated PRP, when used to treat OA in animal models, has both clinical (80% of studies) and disease-modifying effects (68% of studies) [92].
The observed disease-modifying effects of PRP included a reduction in cartilage disease progression and synovial inflammation in OA, along with changes in biomarker levels following PRP administration. PRP was noted to significantly reduce synovial fluid concentrations of biomarkers related to inflammation including cartilage oligomeric matrix protein or (COMP), serum and synovial fluid levels of TNF-a, IL-1β, and prostaglandin E2 (PGE2) levels, and mRNA expression of MMPs [92]. The authors found that PRP significantly increased serum levels of platelet-derived growth factor-A (PDGF-A) and vascular endothelial growth factor (VEGF) and reduced the OA research society international (OARSI) score. Interestingly, VEGF has been shown to be detrimental to cartilage repair in OA [93,94] with further evidence in studies that focussed on factors like using anti-VEGF antibody as a therapeutic approach towards post-traumatic OA [95] or by VEGF attenuation in PRP which enhanced repair in rat OA cartilage [96]. Another study demonstrated that the use of Alendronate (used for the treatment of osteoporosis) in animals, via the inhibition of the nuclear factor kappa-B (NF-κB) signalling pathway [97]. These studies indicated a decrease in the production of inflammation, inflammatory markers, attenuation of cartilage damage and delay in OA progression with the use of PRP [91,97]. All of these parameters are closely related to senescence, a hallmark of aging. However, none of these studies explored the direct association with senescence or any anti-aging potential of PRP.
In contrast, the anti-aging potential of PRP has found extensive applications in fields like dermatology, plastic surgery and overall wound healing [98]. It has been utilised in treating androgenic alopecia, with multiple randomised controlled trials (RCTs) reporting increased hair count, density and thickness among patients who underwent PRP treatment [99,100,101,102]. However, no correlation has been established between platelet count, PDGF, epidermal growth factor (EGF), VEGF levels and clinical improvement (hair count, hair density) [102]. While some meta-analyses have noted improved healing rates, faster healing times and better scar evaluation scores in burn wounds treated with PRP [103], others have found that PRP offers no additional advantage over control in reducing wound infection rates in cases of sternal wounds [104] and burn wounds [103]. Additionally, an RCT that examined the application of autologous leukocyte PRP on the wounds of patients who underwent total hip replacement suggested that leukocyte PRP might expedite complete wound healing, implying a potential role for EGF receptor agonists in promoting wound healing [105].

4. Anti-Aging Potential of PRP for ARDs

4.1. Current Evidence in Literature

The evidence outlined above suggests that while there have been cases when PRP may not have indicated additional benefits in tissue regeneration in comparison to control/placebo; there are, however, multiple indications of the potential of PRP for hair regeneration [102], skin aging [106], wound healing [107], joint repair with and without the combination of MSCs [28,72,108]. We know that inflammation, inflammaging, tissue damage and senescence contribute to aging and ARDs. With the advancement of age, it is well-established that an accumulation of damage leads to cellular senescence and secretion of SASP [2,37,38]. SASP is detected by the presence of pro-inflammatory cytokines and low-grade inflammation (or inflammaging), which eventually leads to the declined ability of tissues to regenerate and repair [10,61,62,69], especially in the case of OA [6,8,48,49,64]. Thus, if PRP has increasingly been used for tissue repair and regeneration with an increasing body of evidence for senescence and inflammation (Table 1), it merits investigation of the anti-aging potential of PRP as well (Figure 1).
A study by Cole et al. in 2017 found that while PRP treatment was comparable to HA treatment regarding WOMAC pain score, their observations and results found that PRP potentially played an anti-inflammatory role for n = 49 OA patients [12]. The anti-inflammatory effect of PRP was also observed in a study by Zhang et al. for in vitro rabbit cells and in vivo mouse models, and it was estimated to do so via hepatocyte growth factor (HGF) [109]. Apart from these, another animal study with old mice indicated that intravenous (IV) administration of PRP increased locomotion, enhanced cognitive function and reduced anxiety and depression-like symptoms [35]. More interestingly, Cakiroglu et al. investigated the effect of autologous intra-ovarian PRP injections in women suffering from primary ovarian insufficiency (POI) to see if PRP improved in vitro fertilisation (IVF) outcomes. Post-PRP treatment, 7.4% of women conceived simultaneously and 64.8% developed antral follicles and were able to attempt IVF [110].
Table 1 below outlines these and similar studies that indicate results for the regenerative and angiogenic properties, tissue regenerative abilities, anti-inflammatory role, analgesic and anti-senescence effects of PRP, indirectly connecting it all with the anti-aging potential of PRP.
Table 1. List of studies investigating the anti-aging potential of PRP via several parameters.
Table 1. List of studies investigating the anti-aging potential of PRP via several parameters.
PRP UsedModelPRP DetailsTarget Disease/OrganSenescence/Aging-Related Parameters TestedMain Age-Related FindingsRef.
Autologous IA PRPIn vivo: prospective, double-blinded, comparative RCT between PRP and HALeukocyte poor, single spin, PRP average volume of 4 mLKnee OAInflammatory/catabolic markers by ELISA and pain scores (WOMAC, IKDC, VAS)PRP indicated significantly better outcomes at weeks 24 and 52. Additionally, PRP treatment decreased the secretion of two pro-inflammatory cytokines, i.e., IL-1β and TNF-α[12]
Human PRP releasate coated onto porous collagen-glycosaminoglycans (GAG) scaffoldsIn vitro: human bone marrow mesenchymal stromal cells (MSCs) and human pooled endothelial cellsPlatelet concentration of 1 × 106/mL formulated into PRP releasateSkin wound healing applicationProliferation, migration, angiogenesis, vascularisation, macrophage polarisationPRP-coated scaffold exhibited enhanced angiogenic and vascularisation potential. It also indicated a lower release of pro-inflammatory markers when exposed to an inflammatory environment[30]
Autologous IA and IO PRP for patient treatment before cell isolationEx vivo: human bone marrow MSCsLiquid PRP
IA: 8 mL and IO: 10 mL volumes, respectively		Hip OAMSC proliferation, SA-β-gal, gene expressionEnhanced MSC proliferation and stress resistance capacities in older MSC donors treated with PRP[32]
Healthy male New Zealand white rabbit PRP; cell culture treatedIn vitro: murine dermal fibroblasts1%, 5% and 10% PRP diluted in 1%FBS for in vitro culturesSenescence associated phenotypes in photo agingCell morphology, SA-β-gal, cell cycle arrest, ECM, ROSPRP prevented cell cycle arrest, reduced SA-β-gal, increased ECM collagen and decreased MMPs. PRP may counteract cell senescence in MSK[34]
Allogenic, IV PRPIn vivo: senescent female BALB/c mice (16–18 months old); n = 46Not providedCognitive aging in senescent miceBehavioural and cognitive: open-field, elevated plus maze, tail suspension, and Morris water maze testPRP increased locomotion, improved memory, reduced anxiety and depression-like behaviour in old mice; enhanced cognitive function with PRP[35]
Enhanced PRP (ePRP) powder prepared by freeze-drying PRP from human patientsIn vitro: human dermal fibroblastsPlatelet count: 1 × 109/mL lyophilised powder reconstituted with 1 mL mediaWound healing in fibroblasts in vitroProliferation, wound healing, qPCR, intracellular ATP measurement, SA-β-gal, metabolic fluxePRP stimulates wound healing by releasing growth factors, increased anti-oxidant production, halts the senescence progression of fibroblasts by activating SIRT1 expression[107]
PRP prepared from rabbit/mouse used for the studyIn vitro and in vivo: rabbit tendon cells in vitro studies and mice for in vivo studiesIn vitro: 10%PRP and in vivo: 10 mL PRPInjured tendonsIn vitro—COX-1, COX-2, mPGES levels by gene expression, Western blotting and immunostaining; in vivo—immunohistochemistryPRP treatment suppressed tendon cell inflammation in vitro and tendon inflammation in vivo, at least partially mediated by HGF in PRP[109]
Intra-ovarian delivery of autologous PRPIn vivo: women with primary ovarian insufficiency (POI)2–4 mL of PRP was injected underneath the ovarian cortexOvarian stimulation and IVF outcome in women with POIAntral follicular count, follicle-stimulating hormone, IVF, clinical pregnancyPRP treatment aided conception in women suffering from POI, with 7.4% of the women being able to conceive spontaneously after PRP treatment[110]
Human PRP is used to treat NIH3T3 cells to be transplanted in vivoIn vivo: genetically modified NIH3T3 embryonic fibroblasts with an enhanced green fluorescent protein (NIH3T3-G) differentiated into osteoblasts transplanted into variectomized senescence-accelerated mouse prone substrain 8 (OVX-SAMP8 mice)Not providedBone regeneration applications in osteoporosis and conditions associated with accelerated agingMolecular imaging and immunohistochemistry(PRP/NIH3T3-G) engraftment prevented the development of osteoporosis, and the life span of OVX-SAMP8 mice receiving PRP/NIH3T3-G transplantation was significantly prolonged[111]
PRP—Platelet rich plasma, IA—intra articular, IO—intra osseous, IV—intra venous, RCT—randomised controlled trial, HA—hyaluronic acid, BALB/c—Bagg Albino mice, ELISA—enzyme-linked immunosorbent assay, WOMAC—Western Ontario and McMaster Universities Osteoarthritis index, IKDC—International knee documentation committee, VAS—Visual analogue scale, SA-β-gal—senescence-associated beta-galactosidase, ECM—extracellular matrix, ROS—reactive oxygen species, qPCR—quantitative polymerised chain reaction, ATP—adenosine triphosphate, COX-1,2—Cyclooxygenase 1, 2, mPGES—microsomal prostaglandin e-synthase, IVF—in vitro fertilisation, IL-1β—interleukin 1-beta, TNF-α tumour necrosis factor-alpha, MSK—musculoskeletal, SIRT1- Sirtuin 1, HGF—hepatocyte growth factor.

4.2. Potential Mechanism of Action (MOA)

PRP has already been established for its anti-aging properties in the field of dermatology and skin care, as outlined earlier. However, the exact mechanism underpinning the effect of PRP remains to be established. With respect to skin aging, it has been reported that injecting PRP into aging skin activates a series of cellular reactions, and cellulose, fibronectin and vitronectin from the PRP aggregate with the growth factors and act locally at the injected site [18]. These proteins potentially act as scaffolds for nascent cells and tissues to advance the repair of aging skin by inducing DNA synthesis and promoting corresponding gene expression at the cellular level [17,112,113] Use of PRP on aging skin resulted in increased reticular dermis thickness by deposition of collagen and elastin fibres [113], and an in vitro model indicated that PRP treated aging skin ameliorated photo aging of the skin via inhibition of MMP-1 and tyrosinase upregulation and by inducing tropoelastin and fibrillin expressions [17].
Regarding regenerative medicine applications of PRP other than dermatology, our knowledge of its action is increasing, but the exact mechanisms are yet to be elucidated [114]. It has, however, been established that platelets remain inactive inside PRP until injected into the injury site, where upon contact with tissue factor—platelets change shape and develop pseudopods to promote platelet aggregation [20]. The activated platelets at the site of injury function via PDGF, VEGF, TGF-b and EGF to promote cellular processes leading to angiogenesis, regeneration, proliferation and bone healing [115].
Platelets are anucleate blood cells produced mainly by megakaryocytes in the bone marrow that are 2–4 mm in diameter with a life span of 7–10 days, with approximately 1011 platelets produced daily [116]. In contrast, fibroblasts are reported to have a life span of 270 days in vitro [117], osteoblasts have a life span of 1–200 days, bone lining cells may live up to 1–10 years, and osteocytes can live up to 50 years [118]. Considering the long life span of these bone cells, it can be acknowledged that they accumulate considerable amount of cellular damage leading to SCs and SASP. On the other hand, platelets renew every 7–10 days, indicating that senescence may not be as deep seated in them. The release of growth factors and cytokines in platelet granules accelerates tissue repair, and this process is further enhanced once combined with fibrinolytic systems [119]. This may be one of the mechanisms by which PRP portrays regenerative and, ultimately, anti-aging properties.

5. Limitations, Conclusions and Future Directions

A critical shortcoming of PRP is its inconsistency, which applies not just to the nomenclature (such as LR-PRP, LP-PRP and so forth) but also to the required formulation, i.e., concentrate, gel, etc., to utilise its benefits to its highest potential. This problem is typically mitigated by adjusting the formulation to suit the specific requirements of each project. Nevertheless, standardising these formulations could definitively establish the influence of PRP, particularly in exploring its impact on aging and ARDs. Another difficulty lies in navigating the intricate network of age-related alterations. Aging itself is exceedingly complex, and now, with 12 recognised hallmarks, the number of aspects requiring exploration to comprehend the anti-aging properties of PRP continues to expand. Before initiating the investigation, each study or trial must judiciously select which hallmarks or parameters align most appropriately with their research goals. Furthermore, considering the existing studies that have observed improvements, and others that have not with PRP treatment [89], it is plausible that for effective PRP therapies, autologous PRP will need to be specifically tailored for each patient or case, resonating with the concept of precision medicine [120].
Ideally, OA clinical trials or studies investigating the effect of PRP must include tests for quantifying senescence and its markers as regular screening. Trials focussing on IO and/or IA PRP injections would have a higher ability to locally impact more SCs as these methods would reach closer to the longest living cells in the bone that would have accumulated considerable SCs and SASP. Serum levels of pro-inflammatory cytokines by ELISA from these patients, along with quantification of SC from inside the bone marrow cells using SA-b-gal assays, are feasible methods [32] and would help shed light on the anti-senescence effect of PRP treatment in OA, which is an ARD. Additionally, with the previous literature indicating that factors/proteins/microenvironment from younger donors can potentially regenerate tissues in older donors [43,121,122,123], it will be worth exploring the application of allogenic PRP from younger donors to patients with OA and eventually, in other ARDs.
Although we are not alone in introducing the concept of PRP as a potential anti-aging solution for age-related diseases (ARDs) [20], to the best of our knowledge, this is the inaugural perspective that provides evidence linking the use of PRP to both aging and age-associated factors of inflammation, inflammaging and senescence that ultimately lead to ARDs. PRP’s functionalities span numerous applications, including analgesics, anti-inflammatory, anti-senescent and angiogenesis (Table 1). Based on the currently available evidence, this perspective is unique in its exclusive focus on PRP’s anti-aging potential. While PRP has not always been shown to enhance tissue regeneration, we believe that with the appropriate optimisation of concentration and modification of its formulations, PRP can intervene in age-related transformations, thereby slowing the progression of ARDs.
In the future, experimental medicine that optimises PRP concentration for patient use could elucidate the mechanisms behind PRP’s anti-aging effects. Double-blinded RCTs assessing PRP’s impact on ARDs will assist in identifying the phenotypes that respond positively to PRP exposure. Long-term investigations and advanced examinations at the cellular and genetic levels, using state-of-the-art techniques such as next-generation sequencing, will help reveal new pathways that could serve as potential therapeutic targets in the future [124].

Author Contributions

Conceptualisation, P.G. and E.J.; software, J.V., P.G. and N.I.; resources, P.G.; writing—original draft preparation, J.V. and P.G.; writing—review and editing, N.I., P.G. and E.J.; visualisation, P.G. and E.J.; funding acquisition, P.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. Ageing and Health. 2022. Available online: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health (accessed on 5 April 2023).
  2. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The Hallmarks of Aging. Cell 2013, 153, 1194–1217. [Google Scholar] [CrossRef] [PubMed]
  3. Schmauck-Medina, T.; Molière, A.; Lautrup, S.; Zhang, J.; Chlopicki, S.; Madsen, H.B.; Cao, S.; Soendenbroe, C.; Mansell, E.; Vestergaard, M.B.; et al. New hallmarks of ageing: A 2022 Copenhagen ageing meeting summary. Aging 2022, 14, 6829–6839. [Google Scholar] [CrossRef] [PubMed]
  4. Ganguly, P.; El-Jawhari, J.J.; Giannoudis, P.V.; Burska, A.N.; Ponchel, F.; Jones, E.A. Age-related Changes in Bone Marrow Mesenchymal Stromal Cells: A Potential Impact on Osteoporosis and Osteoarthritis Development. Cell Transplant. 2017, 26, 1520–1529. [Google Scholar] [CrossRef] [PubMed]
  5. Cross, M.; Smith, E.; Hoy, D.; Nolte, S.; Ackerman, I.; Fransen, M.; Bridgett, L.; Williams, S.; Guillemin, F.; Hill, C.L.; et al. The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study. Ann. Rheum. Dis. 2014, 73, 1323–1330. [Google Scholar] [CrossRef]
  6. Jeon, O.H.; David, N.; Campisi, J.; Elisseeff, J.H. Senescent cells and osteoarthritis: A painful connection. J. Clin. Investig. 2018, 128, 1229–1237. [Google Scholar] [CrossRef]
  7. Zhang, X.-X.; He, S.-H.; Liang, X.; Li, W.; Li, T.-F.; Li, D.-F. Aging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis. Front. Pharmacol. 2021, 12, 728100. [Google Scholar] [CrossRef]
  8. Liu, Y.; Zhang, Z.; Li, T.; Xu, H.; Zhang, H. Senescence in osteoarthritis: From mechanism to potential treatment. Arthritis Res. Ther. 2022, 24, 174. [Google Scholar] [CrossRef]
  9. Rizzo, M.G.; Best, T.M.; Huard, J.; Philippon, M.; Hornicek, F.; Duan, Z.; Griswold, A.J.; Kaplan, L.D.; Hare, J.M.; Kouroupis, D. Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents. Cells 2023, 12, 1421. [Google Scholar] [CrossRef]
  10. Olivieri, F.; Prattichizzo, F.; Grillari, J.; Balistreri, C.R. Cellular Senescence and Inflammaging in Age-Related Diseases. Mediat. Inflamm. 2018, 2018, 9076485. [Google Scholar] [CrossRef]
  11. Sánchez, M.; Fiz, N.; Azofra, J.; Usabiaga, J.; Recalde, E.A.; Gutierrez, A.G.; Albillos, J.; Gárate, R.; Aguirre, J.J.; Padilla, S.; et al. A Randomized Clinical Trial Evaluating Plasma Rich in Growth Factors (PRGF-Endoret) Versus Hyaluronic Acid in the Short-Term Treatment of Symptomatic Knee Osteoarthritis. Arthrosc. J. Arthrosc. Relat. Surg. 2012, 28, 1070–1078. [Google Scholar] [CrossRef]
  12. Cole, B.J.; Karas, V.; Hussey, K.; Merkow, D.B.; Pilz, K.; Fortier, L.A. Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis. Am. J. Sports Med. 2017, 45, 339–346. [Google Scholar] [CrossRef] [PubMed]
  13. Kon, E.; Di Matteo, B.; Delgado, D.; Cole, B.J.; Dorotei, A.; Dragoo, J.L.; Filardo, G.; Fortier, L.A.; Giuffrida, A.; Jo, C.H.; et al. Platelet-rich plasma for the treatment of knee osteoarthritis: An expert opinion and proposal for a novel classification and coding system. Expert Opin. Biol. Ther. 2020, 20, 1447–1460. [Google Scholar] [CrossRef] [PubMed]
  14. Sánchez, M.; Beitia, M.; Pompei, O.; Jorquera, C.; Sánchez, P.; Knörr, J.; Soldado, F.; López, L.; Oraa, J.; Bilbao, A.M.; et al. Isolation, Activation, and Mechanism of Action of Platelet-Rich Plasma and Its Applications for Joint Repair. In Regenerative Medicine; Intechopen: London, UK, 2019. [Google Scholar] [CrossRef]
  15. Foster, T.E.; Puskas, B.L.; Mandelbaum, B.R.; Gerhardt, M.B.; Rodeo, S.A. Platelet-Rich Plasma: From basic science to clinical applications. Am. J. Sports Med. 2009, 37, 2259–2272. [Google Scholar] [CrossRef] [PubMed]
  16. Marx, R.E. Platelet-Rich Plasma (PRP): What Is PRP and What Is Not PRP? Implant. Dent. 2001, 10, 225–228. [Google Scholar] [CrossRef]
  17. Du, R.; Lei, T. Effects of autologous platelet-rich plasma injections on facial skin rejuvenation. Exp. Ther. Med. 2020, 19, 3024–3030. [Google Scholar] [CrossRef]
  18. Pavlovic, V.; Ciric, M.; Jovanovic, V.; Stojanovic, P. Platelet Rich Plasma: A short overview of certain bioactive components. Open Med. 2016, 11, 242–247. [Google Scholar] [CrossRef]
  19. Wang, H.L.; Avila, G. Platelet rich plasma: Myth or reality? Eur. J. Dent. 2007, 1, 192–194. [Google Scholar] [CrossRef]
  20. Everts, P.; Onishi, K.; Jayaram, P.; Lana, J.F.; Mautner, K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int. J. Mol. Sci. 2020, 21, 7794. [Google Scholar] [CrossRef]
  21. NICE. Platelet-Rich Plasma Injections for Knee Osteoarthritis. Available online: https://www.nice.org.uk/guidance/ipg637 (accessed on 5 April 2023).
  22. Bansal, H.; Leon, J.; Pont, J.L.; Wilson, D.A.; Bansal, A.; Agarwal, D.; Preoteasa, I. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Sci. Rep. 2021, 11, 3971. [Google Scholar] [CrossRef]
  23. Bennell, K.L.; Paterson, K.L.; Metcalf, B.R.; Duong, V.; Eyles, J.; Kasza, J.; Wang, Y.; Cicuttini, F.; Buchbinder, R.; Forbes, A.; et al. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA 2021, 326, 2021–2030. [Google Scholar] [CrossRef]
  24. Gentile, P.; Garcovich, S. Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy. Int. J. Mol. Sci. 2020, 21, 2702. [Google Scholar] [CrossRef]
  25. Paichitrojjana, A. Platelet Rich Plasma and Its Use in Hair Regrowth: A Review. Drug Des. Dev. Ther. 2022, 16, 635–645. [Google Scholar] [CrossRef]
  26. Gentile, P.; Garcovich, S. Systematic Review—The Potential Implications of Different Platelet-Rich Plasma (PRP) Concentrations in Regenerative Medicine for Tissue Repair. Int. J. Mol. Sci. 2020, 21, 5702. [Google Scholar] [CrossRef] [PubMed]
  27. Kawabata, S.; Akeda, K.; Yamada, J.; Takegami, N.; Fujiwara, T.; Fujita, N.; Sudo, A. Advances in Platelet-Rich Plasma Treatment for Spinal Diseases: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 7677. [Google Scholar] [CrossRef] [PubMed]
  28. Delgado, D.; Garate, A.; Sánchez, P.; Bilbao, A.M.; del Caño, G.G.; Salles, J.; Sánchez, M. Biological and structural effects after intraosseous infiltrations of age-dependent platelet-rich plasma: An in vivo study. J. Orthop. Res. 2020, 38, 1931–1941. [Google Scholar] [CrossRef] [PubMed]
  29. Xu, J.; Gou, L.; Zhang, P.; Li, H.; Qiu, S. Platelet-rich plasma and regenerative dentistry. Aust. Dent. J. 2020, 65, 131–142. [Google Scholar] [CrossRef] [PubMed]
  30. Do Amaral, R.J.F.C.; Zayed, N.M.A.; Pascu, E.I.; Cavanagh, B.; Hobbs, C.; Santarella, F.; Simpson, C.R.; Murphy, C.M.; Sridharan, R.; González-Vázquez, A.; et al. Functionalising Collagen-Based Scaffolds With Platelet-Rich Plasma for Enhanced Skin Wound Healing Potential. Front. Bioeng. Biotechnol. 2019, 7, 371. [Google Scholar] [CrossRef] [PubMed]
  31. Tian, J.; Lei, X.X.; Xuan, L.; Tang, J.B.; Cheng, B. The effects of aging, diabetes mellitus, and antiplatelet drugs on growth factors and anti-aging proteins in platelet-rich plasma. Platelets 2019, 30, 773–792. [Google Scholar] [CrossRef]
  32. Ganguly, P.; Fiz, N.; Beitia, M.; Owston, H.E.; Delgado, D.; Jones, E.; Sánchez, M. Effect of Combined Intraosseous and Intraarticular Infiltrations of Autologous Platelet-Rich Plasma on Subchondral Bone Marrow Mesenchymal Stromal Cells from Patients with Hip Osteoarthritis. J. Clin. Med. 2022, 11, 3891. [Google Scholar] [CrossRef]
  33. Ruan, D.; Tang, C.; Fei, Y.; Qian, S.; Xiang, X.; Xu, J.; Huang, Z.; Chen, X.; Heng, B.C.; Yin, Z.; et al. Early-Stage Primary Anti-inflammatory Therapy Enhances the Regenerative Efficacy of Platelet-Rich Plasma in a Rabbit Achilles Tendinopathy Model. Am. J. Sports Med. 2021, 49, 3357–3371. [Google Scholar] [CrossRef]
  34. Jia, C.; Lu, Y.; Bi, B.; Chen, L.; Yang, Q.; Yang, P.; Guo, Y.; Zhu, J.; Zhu, N.; Liu, T. Platelet-rich plasma ameliorates senescence-like phenotypes in a cellular photoaging model. RSC Adv. 2017, 7, 3152–3160. [Google Scholar] [CrossRef]
  35. Demir, E.A.; Karagoz, M. Platelet-Rich Plasma (PRP) is a Potential Self-Sourced Cognition Booster in Elderly Mice. Exp. Aging Res. 2020, 46, 139–153. [Google Scholar] [CrossRef] [PubMed]
  36. Hayflick, L.; Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25, 585–621. [Google Scholar] [CrossRef]
  37. Campisi, J.; d’Adda di Fagagna, F. Cellular senescence: When bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8, 729–740. [Google Scholar] [CrossRef] [PubMed]
  38. Rodier, F.; Campisi, J. Four faces of cellular senescence. J. Cell Biol. 2011, 192, 547–556. [Google Scholar] [CrossRef]
  39. Zhai, W.; Tan, J.; Russell, T.; Chen, S.; McGonagle, D.; Naing, M.W.; Yong, D.; Jones, E. Multi-pronged approach to human mesenchymal stromal cells senescence quantification with a focus on label-free methods. Sci. Rep. 2021, 11, 1054. [Google Scholar] [CrossRef]
  40. Olivieri, F.; Albertini, M.C.; Orciani, M.; Ceka, A.; Cricca, M.; Procopio, A.D.; Bonafè, M. DNA damage response (DDR) and senescence: Shuttled inflamma-miRNAs on the stage of inflamm-aging. Oncotarget 2015, 6, 35509–35521. [Google Scholar] [CrossRef]
  41. D’adda Di Fagagna, F. Living on a break: Cellular senescence as a DNA-damage response. Nat. Rev. Cancer 2008, 8, 512–522. [Google Scholar] [CrossRef]
  42. Rodier, F.; Coppé, J.-P.; Patil, C.K.; Hoeijmakers, W.A.M.; Muñoz, D.P.; Raza, S.R.; Freund, A.; Campeau, E.; Davalos, A.R.; Campisi, J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11, 973–979. [Google Scholar] [CrossRef]
  43. Ganguly, P.; El-Jawhari, J.J.; Burska, A.N.; Ponchel, F.; Giannoudis, P.V.; Jones, E.A. The Analysis of In Vivo Aging in Human Bone Marrow Mesenchymal Stromal Cells Using Colony-Forming Unit-Fibroblast Assay and the CD45lowCD271+ Phenotype. Stem Cells Int. 2019, 2019, 5197983. [Google Scholar] [CrossRef]
  44. Schultz, M.B.; Sinclair, D.A. When stem cells grow old: Phenotypes and mechanisms of stem cell aging. Development 2016, 143, 3–14. [Google Scholar] [CrossRef] [PubMed]
  45. Drummond-Barbosa, D. Stem Cells, Their Niches and the Systemic Environment: An Aging Network. Genetics 2008, 180, 1787–1797. [Google Scholar] [CrossRef] [PubMed]
  46. Campisi, J. Aging, Cellular Senescence, and Cancer. Annu. Rev. Physiol. 2013, 75, 685–705. [Google Scholar] [CrossRef] [PubMed]
  47. Krizhanovsky, V.; Xue, W.; Zender, L.; Yon, M.; Hernando, E.; Lowe, S. Implications of Cellular Senescence in Tissue Damage Response, Tumor Suppression, and Stem Cell Biology. Cold Spring Harb. Symp. Quant. Biol. 2008, 73, 513–522. [Google Scholar] [CrossRef] [PubMed]
  48. Xie, J.; Wang, Y.; Lu, L.; Liu, L.; Yu, X.; Pei, F. Cellular senescence in knee osteoarthritis: Molecular mechanisms and therapeutic implications. Ageing Res. Rev. 2021, 70, 101413. [Google Scholar] [CrossRef]
  49. Coryell, P.R.; Diekman, B.O.; Loeser, R.F. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat. Rev. Rheumatol. 2021, 17, 47–57. [Google Scholar] [CrossRef]
  50. Wan, M.; Gray-Gaillard, E.F.; Elisseeff, J.H. Cellular senescence in musculoskeletal homeostasis, diseases, and regeneration. Bone Res. 2021, 9, 41. [Google Scholar] [CrossRef]
  51. Chang, J.; Wang, Y.; Shao, L.; Laberge, R.-M.; DeMaria, M.; Campisi, J.; Janakiraman, K.; Sharpless, N.E.; Ding, S.; Feng, W.; et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 2016, 22, 78–83. [Google Scholar] [CrossRef]
  52. Jeon, O.H.; Kim, C.; Laberge, R.-M.; DeMaria, M.; Rathod, S.; Vasserot, A.P.; Chung, J.W.; Kim, D.H.; Poon, Y.; David, N.; et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 2017, 23, 775–781. [Google Scholar] [CrossRef]
  53. Walaszczyk, A.; Dookun, E.; Redgrave, R.; Tual-Chalot, S.; Victorelli, S.; Spyridopoulos, I.; Owens, A.; Arthur, H.M.; Passos, J.F.; Richardson, G.D. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging Cell 2019, 18, e12945. [Google Scholar] [CrossRef]
  54. Lopes-Paciencia, S.; Saint-Germain, E.; Rowell, M.-C.; Ruiz, A.F.; Kalegari, P.; Ferbeyre, G. The senescence-associated secretory phenotype and its regulation. Cytokine 2019, 117, 15–22. [Google Scholar] [CrossRef] [PubMed]
  55. Byun, H.-O.; Lee, Y.-K.; Kim, J.-M.; Yoon, G. From cell senescence to age-related diseases: Differential mechanisms of action of senescence-associated secretory phenotypes. BMB Rep. 2015, 48, 549–558. [Google Scholar] [CrossRef] [PubMed]
  56. Gorgoulis, V.; Adams, P.D.; Alimonti, A.; Bennett, D.C.; Bischof, O.; Bishop, C.; Campisi, J.; Collado, M.; Evangelou, K.; Ferbeyre, G.; et al. Cellular Senescence: Defining a Path Forward. Cell 2019, 179, 813–827. [Google Scholar] [CrossRef] [PubMed]
  57. Cuollo, L.; Antonangeli, F.; Santoni, A.; Soriani, A. The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases. Biology 2020, 9, 485. [Google Scholar] [CrossRef]
  58. Franceschi, C.; Bonafe, M.; Valensin, S.; Olivieri, F.; De Luca, M.; Ottaviani, E.; De Benedictis, G. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000, 908, 244–254. [Google Scholar] [CrossRef]
  59. De Martinis, M.; Franceschi, C.; Monti, D.; Ginaldi, L. Inflammation markers predicting frailty and mortality in the elderly. Exp. Mol. Pathol. 2006, 80, 219–227. [Google Scholar] [CrossRef]
  60. Vasto, S.; Candore, G.; Balistreri, C.R.; Caruso, M.; Colonna-Romano, G.; Grimaldi, M.P.; Listi, F.; Nuzzo, D.; Lio, D.; Caruso, C. Inflammatory networks in ageing, age-related diseases and longevity. Mech. Ageing Dev. 2007, 128, 83–91. [Google Scholar] [CrossRef]
  61. Baylis, D.; Bartlett, D.B.; Patel, H.P.; Roberts, H.C. Understanding how we age: Insights into inflammaging. Longev. Heal. 2013, 2, 8. [Google Scholar] [CrossRef]
  62. Franceschi, C.; Campisi, J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. J. Gerontol. A Ser. Biol. Sci. Med. Sci. 2014, 69 (Suppl. 1), S4–S9. [Google Scholar] [CrossRef]
  63. Franceschi, C.; Garagnani, P.; Vitale, G.; Capri, M.; Salvioli, S. Inflammaging and ‘Garb-aging’. Trends Endocrinol. Metab. 2017, 28, 199–212. [Google Scholar] [CrossRef]
  64. Rezuș, E.; Cardoneanu, A.; Burlui, A.; Luca, A.; Codreanu, C.; Tamba, B.I.; Stanciu, G.-D.; Dima, N.; Bădescu, C.; Rezuș, C. The Link Between Inflammaging and Degenerative Joint Diseases. Int. J. Mol. Sci. 2019, 20, 614. [Google Scholar] [CrossRef]
  65. Farr, J.N.; Khosla, S. Cellular senescence in bone. Bone 2019, 121, 121–133. [Google Scholar] [CrossRef] [PubMed]
  66. Farr, J.N.; Fraser, D.G.; Wang, H.; Jaehn, K.; Ogrodnik, M.B.; Weivoda, M.M.; Drake, M.T.; Tchkonia, T.; LeBrasseur, N.K.; Kirkland, J.L.; et al. Identification of Senescent Cells in the Bone Microenvironment. J. Bone Miner. Res. 2016, 31, 1920–1929. [Google Scholar] [CrossRef] [PubMed]
  67. Scanzello, C.R. Role of low-grade inflammation in osteoarthritis. Curr. Opin. Rheumatol. 2017, 29, 79–85. [Google Scholar] [CrossRef] [PubMed]
  68. Harrison, M.H.M.; Schajowicz, F.; Trueta, J. Osteoarthritis of the hip: A study of the nature and evolution of the disease. J. Bone Jt. Surg. 1953, 35-B, 598–626. [Google Scholar] [CrossRef]
  69. Fulop, T.; Witkowski, J.M.; Olivieri, F.; Larbi, A. The integration of inflammaging in age-related diseases. Semin. Immunol. 2018, 40, 17–35. [Google Scholar] [CrossRef]
  70. Santoro, A.; Martucci, M.; Conte, M.; Capri, M.; Franceschi, C.; Salvioli, S. Inflammaging, hormesis and the rationale for anti-aging strategies. Ageing Res. Rev. 2020, 64, 101142. [Google Scholar] [CrossRef]
  71. Sánchez, M.; Delgado, D.; Sánchez, P.; Muiños-López, E.; Paiva, B.; Granero-Moltó, F.; Prósper, F.; Pompei, O.; Pérez, J.C.; Azofra, J.; et al. Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study. BioMed Res. Int. 2016, 2016, 4868613. [Google Scholar] [CrossRef]
  72. Zhao, J.; Liang, G.; Han, Y.; Yang, W.; Xu, N.; Luo, M.; Pan, J.; Liu, J.; Zeng, L.-F. Combination of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) in the treatment of knee osteoarthritis: A meta-analysis of randomised controlled trials. BMJ Open 2022, 12, e061008. [Google Scholar] [CrossRef]
  73. Su, K.; Bai, Y.; Wang, J.; Zhang, H.; Liu, H.; Ma, S. Comparison of hyaluronic acid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis. Clin. Rheumatol. 2018, 37, 1341–1350. [Google Scholar] [CrossRef]
  74. Paterson, K.L.; Hunter, D.J.; Metcalf, B.R.; Eyles, J.; Duong, V.; Kazsa, J.; Wang, Y.; Buchbinder, R.; Cicuttini, F.; Forbes, A.; et al. Efficacy of intra-articular injections of platelet-rich plasma as a symptom- and disease-modifying treatment for knee osteoarthritis—The RESTORE trial protocol. BMC Musculoskelet. Disord. 2018, 19, 272. [Google Scholar] [CrossRef] [PubMed]
  75. Mojica, E.S.; Markus, D.H.; Hurley, E.T.; Blaeser, A.M.; Jazrawi, L.M.; Campbell, K.A.; Strauss, E.J. Estimated Time to Maximum Medical Improvement of Intra-articular Injections in the Treatment of Knee Osteoarthritis—A Systematic Review. Arthroscopy 2022, 38, 980–988.e4. [Google Scholar] [CrossRef] [PubMed]
  76. Roffi, A.; Di Matteo, B.; Krishnakumar, G.S.; Kon, E.; Filardo, G. Platelet-rich plasma for the treatment of bone defects: From pre-clinical rational to evidence in the clinical practice. A systematic review. Int. Orthop. 2017, 41, 221–237. [Google Scholar] [CrossRef]
  77. Zamani, M.; Yaghoubi, Y.; Movassaghpour, A.; Shakouri, K.; Mehdizadeh, A.; Pishgahi, A.; Yousefi, M. Novel therapeutic approaches in utilising platelet lysate in regenerative medicine: Are we ready for clinical use? J. Cell. Physiol. 2019, 234, 17172–17186. [Google Scholar] [CrossRef]
  78. Soares, C.S.; Babo, P.S.; Reis, R.L.; Carvalho, P.P.; Gomes, M.E. Platelet-Derived Products in Veterinary Medicine: A New Trend or an Effective Therapy? Trends Biotechnol. 2020, 39, 225–243. [Google Scholar] [CrossRef] [PubMed]
  79. Vun, J.; Panteli, M.; Jones, E.; Giannoudis, P. The in vitro effects of platelet products on the biophysiological functions of human bone marrow mesenchymal stromal cells: A systematic review. Eur. Cells Mater. 2021, 41, 269–315. [Google Scholar] [CrossRef]
  80. Dohan Ehrenfest, D.M.; Rasmusson, L.; Albrektsson, T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009, 27, 158–167. [Google Scholar] [CrossRef]
  81. Mautner, K.; Malanga, G.A.; Smith, J.; Shiple, B.; Ibrahim, V.; Sampson, S.; Bowen, J.E. A Call for a Standard Classification System for Future Biologic Research: The Rationale for New PRP Nomenclature. PMR 2015, 7 (Suppl. 4), S53–S59. [Google Scholar] [CrossRef]
  82. Lana, J.F.S.D.; Purita, J.; Paulus, C.; Huber, S.C.; Rodrigues, B.L.; Rodrigues, A.A.; Santana, M.H.; Madureira, J.L., Jr.; Luzo, C.M.; Belangero, W.D.; et al. Contributions for classification of platelet rich plasma–proposal of a new classification: MARSPILL. Regen. Med. 2017, 12, 565–574. [Google Scholar] [CrossRef]
  83. DeLong, J.M.; Russell, R.P.; Mazzocca, A.D. Platelet-rich plasma: The paw classification system. Arthrosc. J. Arthrosc. Relat. Surg. 2012, 28, 998–1009. [Google Scholar] [CrossRef]
  84. Mishra, A.; Harmon, K.; Woodall, J.; Vieira, A. Sports Medicine Applications of Platelet Rich Plasma. Curr. Pharm. Biotechnol. 2012, 13, 1185–1195. [Google Scholar] [CrossRef] [PubMed]
  85. Magalon, J.; Chateau, A.L.; Bertrand, B.; Louis, M.L.; Silvestre, A.; Giraudo, L.; Veran, J.; Sabatier, F. DEPA classification: A proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc. Med. 2016, 2, e000060. [Google Scholar] [CrossRef]
  86. Xu, Z.; Hu, H.; Wu, B.; Huang, C.; Liu, Q.; Chen, B. Efficacy of Platelet-Rich Plasma in the Treatment of Fractures: A Meta-Analysis. Comput. Math. Methods Med. 2022, 2022, 5105725. [Google Scholar] [CrossRef]
  87. Yang, J.; Zhang, X.; Liang, W.; Chen, G.; Ma, Y.; Zhou, Y.; Fen, R.; Jiang, K. Efficacy of adjuvant treatment for fracture nonunion/delayed union: A network meta-analysis of randomised controlled trials. BMC Musculoskelet. Disord. 2022, 23, 481. [Google Scholar] [CrossRef] [PubMed]
  88. Tuakli-Wosornu, Y.A.; Terry, A.; Boachie-Adjei, K.; Harrison, J.R.; Gribbin, C.K.; LaSalle, E.E.; Nguyen, J.T.; Solomon, J.L.; Lutz, G.E. Lumbar Intradiskal Platelet-Rich Plasma (PRP) Injections: A Prospective, Double-Blind, Randomized Controlled Study. PMR 2015, 8, 1–10. [Google Scholar] [CrossRef]
  89. Masiello, F.; Pati, I.; Veropalumbo, E.; Pupella, S.; Cruciani, M.; De Angelis, V. Ultrasound-guided injection of platelet-rich plasma for tendinopathies: A systematic review and meta-analysis. Blood Transfus. 2023, 21, 119–136. [Google Scholar] [CrossRef]
  90. Gong, H.; Li, K.; Xie, R.; Du, G.; Li, L.; Wang, S.; Yin, J.; Gu, J.; Wang, P.; Chen, M.; et al. Clinical therapy of platelet-rich plasma vs hyaluronic acid injections in patients with knee osteoarthritis: A systematic review and meta-analysis of randomised double-blind controlled trials. Medicine 2021, 100, e25168. [Google Scholar] [CrossRef] [PubMed]
  91. Laver, d.G.; Lior, L. ESSKA Orthobiologic Initiative (ORBIT): Consensus Process on Blood Derived Products. European Society of Sports Traumatology, Knee Surgery and Arthroscopy. 2022. Available online: https://www.esska.org/news/593282/ESSKA-Orthobiologic-Initiative-ORBIT-Consensus-Process-on-Blood-Derived-Products-.htm (accessed on 1 June 2023).
  92. Boffa, A.; Salerno, M.; Merli, G.; De Girolamo, L.; Laver, L.; Magalon, J.; Sánchez, M.; Tischer, T.; Filardo, G. Platelet-rich plasma injections induce disease-modifying effects in the treatment of osteoarthritis in animal models. Knee Surg. Sports Traumatol. Arthrosc. 2021, 29, 4100–4121. [Google Scholar] [CrossRef] [PubMed]
  93. Hamilton, J.L.; Nagao, M.; Levine, B.R.; Chen, D.; Olsen, B.R.; Im, H.-J. Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. J. Bone Miner. Res. 2016, 31, 11024. [Google Scholar] [CrossRef]
  94. Enomoto, H.; Inoki, I.; Komiya, K.; Shiomi, T.; Ikeda, E.; Obata, K.-I.; Matsumoto, H.; Toyama, Y.; Okada, Y. Vascular Endothelial Growth Factor Isoforms and Their Receptors Are Expressed in Human Osteoarthritic Cartilage. Am. J. Pathol. 2003, 162, 171–181. [Google Scholar] [CrossRef]
  95. Nagai, T.; Sato, M.; Kobayashi, M.; Yokoyama, M.; Tani, Y.; Mochida, J. Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis. Thromb. Haemost. 2014, 16, 427. [Google Scholar] [CrossRef]
  96. Lee, J.S.; Guo, P.; Klett, K.; Hall, M.; Sinha, K.; Ravuri, S.; Huard, J.; Murphy, W.L. VEGF-attenuated platelet-rich plasma improves therapeutic effect on cartilage repair. Biomater. Sci. 2022, 10, 2172–2181. [Google Scholar] [CrossRef] [PubMed]
  97. Xin, F.; Wang, H.; Yuan, F.; Ding, Y. Platelet-Rich Plasma Combined with Alendronate Reduces Pain and Inflammation in Induced Osteoarthritis in Rats by Inhibiting the Nuclear Factor-Kappa B Signaling Pathway. BioMed Res. Int. 2020, 2020, 8070295. [Google Scholar] [CrossRef] [PubMed]
  98. Samadi, P.; Sheykhhasan, M.; Khoshinani, H.M. The Use of Platelet-Rich Plasma in Aesthetic and Regenerative Medicine: A Comprehensive Review. Aesthetic Plast. Surg. 2019, 43, 803–814. [Google Scholar] [CrossRef] [PubMed]
  99. Bayat, M.; Yazdanpanah, M.J.; Alamdari, D.H.; Banihashemi, M.; Salehi, M. The effect of platelet-rich plasma injection in the treatment of androgenetic alopecia. J. Cosmet. Dermatol. 2019, 18, 1624–1628. [Google Scholar] [CrossRef] [PubMed]
  100. Hurley, E.T. Editorial Commentary: Platelet-Rich Plasma for Rotator Cuff Repairs: No Evidence for Improved Long-Term Outcomes … Yet! Arthrosc. J. Arthrosc. Relat. Surg. 2022, 38, 62–64. [Google Scholar] [CrossRef]
  101. Dubin, D.P.; Lin, M.J.; Leight, H.M.; Farberg, A.S.; Torbeck, R.L.; Burton, W.B.; Khorasani, H. The effect of platelet-rich plasma on female androgenetic alopecia: A randomised controlled trial. J. Am. Acad. Dermatol. 2020, 83, 1294–1297. [Google Scholar] [CrossRef]
  102. Rodrigues, B.L.; Montalvão, S.A.; Cancela, R.B.; Silva, F.A.; Urban, A.; Huber, S.C.; Júnior, J.L.R.; Lana, J.F.S.; Annichinno-Bizzacchi, J.M. Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels. J. Am. Acad. Dermatol. 2019, 80, 694–700. [Google Scholar] [CrossRef]
  103. Zheng, W.; Zhao, D.-L.; Zhao, Y.-Q.; Li, Z.-Y. Effectiveness of platelet rich plasma in burn wound healing: A systematic review and meta-analysis. J. Dermatol. Treat. 2022, 33, 131–137. [Google Scholar] [CrossRef]
  104. Yao, D.; Feng, G.; Zhao, F.; Hao, D. Effects of platelet-rich plasma on the healing of sternal wounds: A meta-analysis. Wound Repair Regen. 2021, 29, 153–167. [Google Scholar] [CrossRef]
  105. Capion, S.C.; Jørgensen, H.B.L.; Ågren, M.S.; Daugaard, H.; Ribel-Madsen, S.; Marando, D.; Johansson, P.I.; Salado, J.; Halschou-Jensen, P.M.; Borgwardt, A.; et al. The wound healing effect of local leukocyte platelet-rich plasma after total hip arthroplasty: A randomised controlled trial. Wound Repair Regen. 2021, 29, 988–995. [Google Scholar] [CrossRef] [PubMed]
  106. Maisel-Campbell, A.L.; Ismail, A.; Reynolds, K.A.; Poon, E.; Serrano, L.; Grushchak, S.; Farid, C.; West, D.P.; Alam, M. A systematic review of the safety and effectiveness of platelet-rich plasma (PRP) for skin aging. Arch. Dermatol. Res. 2020, 312, 301–315. [Google Scholar] [CrossRef]
  107. Weng, H.-P.; Cheng, Y.-Y.; Lee, H.-L.; Hsu, T.-Y.; Chang, Y.-T.; Shen, Y.-A. Enhanced Platelet-Rich Plasma (ePRP) Stimulates Wound Healing through Effects on Metabolic Reprogramming in Fibroblasts. Int. J. Mol. Sci. 2021, 22, 12623. [Google Scholar] [CrossRef] [PubMed]
  108. Sánchez, M.; Anitua, E.; Delgado, D.; Sanchez, P.; Prado, R.; Goiriena, J.J.; Prosper, F.; Orive, G.; Padilla, S. A new strategy to tackle severe knee osteoarthritis: Combination of intra-articular and intraosseous injections of Platelet Rich Plasma. Expert Opin. Biol. Ther. 2016, 16, 627–643. [Google Scholar] [CrossRef] [PubMed]
  109. Zhang, J.; Middleton, K.K.; Fu, F.H.; Im, H.-J.; Wang, J.H.-C. HGF Mediates the Anti-inflammatory Effects of PRP on Injured Tendons. PLoS ONE 2013, 8, e67303. [Google Scholar] [CrossRef]
  110. Cakiroglu, Y.; Saltik, A.; Yuceturk, A.; Karaosmanoglu, O.; Kopuk, S.Y.; Scott, R.T.; Tiras, B.; Seli, E. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging 2020, 12, 10211–10222. [Google Scholar] [CrossRef]
  111. Lo, W.-C.; Chiou, J.-F.; Gelovani, J.G.; Cheong, M.-L.; Lee, C.-M.; Liu, H.-Y.; Wu, C.-H.; Wang, M.-F.; Lin, C.-T.; Deng, W.-P. Transplantation of Embryonic Fibroblasts Treated with Platelet-Rich Plasma Induces Osteogenesis in SAMP8 Mice Monitored by Molecular Imaging. J. Nucl. Med. 2009, 50, 765–773. [Google Scholar] [CrossRef]
  112. El-Domyati, M.; Abdel-Wahab, H.; Hossam, A. Combining microneedling with other minimally invasive procedures for facial rejuvenation: A split-face comparative study. Int. J. Dermatol. 2018, 57, 1324–1334. [Google Scholar] [CrossRef]
  113. Charles-De-Sá, L.; Gontijo-De-Amorim, N.F.; Takiya, C.M.; Borojevic, R.; Benati, D.; Bernardi, P.; Sbarbati, A.; Rigotti, G. Effect of Use of Platelet-Rich Plasma (PRP) in Skin with Intrinsic Aging Process. Aesthetic Surg. J. 2018, 38, 321–328. [Google Scholar] [CrossRef]
  114. Szwedowski, D.; Szczepanek, J.; Paczesny, Ł.; Zabrzyński, J.; Gagat, M.; Mobasheri, A.; Jeka, S. The Effect of Platelet-Rich Plasma on the Intra-Articular Microenvironment in Knee Osteoarthritis. Int. J. Mol. Sci. 2021, 22, 5492. [Google Scholar] [CrossRef]
  115. Jain, N.K.; Gulati, M. Platelet-rich plasma: A healing virtuoso. BLOOD Res. 2016, 51, 3–5. [Google Scholar] [CrossRef]
  116. Josefsson, E.C.; Vainchenker, W.; James, C. Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases. Int. J. Mol. Sci. 2020, 21, 7591. [Google Scholar] [CrossRef] [PubMed]
  117. Sturm, G.; Monzel, A.S.; Karan, K.R.; Michelson, J.; Ware, S.A.; Cardenas, A.; Lin, J.; Bris, C.; Santhanam, B.; Murphy, M.P.; et al. A multi-omics longitudinal aging dataset in primary human fibroblasts with mitochondrial perturbations. Sci. Data 2022, 9, 751. [Google Scholar] [CrossRef] [PubMed]
  118. Manolagas, S.C.; Parfitt, A.M. What old means to bone. Trends Endocrinol. Metab. 2010, 21, 369–374. [Google Scholar] [CrossRef]
  119. Dos Santos, R.G.; Santos, G.S.; Alkass, N.; Chiesa, T.L.; Azzini, G.O.; da Fonseca, L.F.; dos Santos, A.F.; Rodrigues, B.L.; Mosaner, T.; Lana, J.F. The regenerative mechanisms of platelet-rich plasma: A review. Cytokine 2021, 144, 155560. [Google Scholar] [CrossRef] [PubMed]
  120. Andia, I. Platelet rich plasma therapies: A great potential to be harnessed. Muscles Ligaments Tendons J. 2014, 4, 1–2. [Google Scholar] [CrossRef] [PubMed]
  121. Conboy, I.M.; Conboy, M.J.; Wagers, A.J.; Girma, E.R.; Weissman, I.L.; Rando, T.A. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005, 433, 760–764. [Google Scholar] [CrossRef] [PubMed]
  122. Karin, O.; Alon, U. Senescent cell accumulation mechanisms inferred from parabiosis. Geroscience 2021, 43, 329–341. [Google Scholar] [CrossRef]
  123. Liu, A.; Guo, E.; Yang, J.; Yang, Y.; Liu, S.; Jiang, X.; Hu, Q.; Dirsch, O.; Dahmen, U.; Zhang, C.; et al. Young plasma reverses age-dependent alterations in hepatic function through the restoration of autophagy. Aging Cell 2018, 17, e12708. [Google Scholar] [CrossRef]
  124. Ganguly, P.; Toghill, B.; Pathak, S. Aging, Bone Marrow and Next-Generation Sequencing (NGS): Recent Advances and Future Perspectives. Int. J. Mol. Sci. 2021, 22, 12225. [Google Scholar] [CrossRef]
Bioengineering 10 00987 g001
Figure 1. Anti-aging potential of PRP. DNA damage leads to cellular senescence and inflammation, which, with advancing age, accumulates SASP and inflammaging factors, respectively. Both contribute towards aging and age-related changes, specifically towards age-related diseases (ARDs) that impact the quality of life (QOL). PRP intervention has been shown to alleviate pain and disease progression in OA and reduce inflammatory markers and senescent cells (indicated in solid green lines), all of which are either precursors of aging or the effect of age-related changes. Investigations focused on the anti-aging property of PRP for age-related diseases (excluding those aimed at cosmetic applications) are yet to be explored and are indicated in the green dotted line.
Figure 1. Anti-aging potential of PRP. DNA damage leads to cellular senescence and inflammation, which, with advancing age, accumulates SASP and inflammaging factors, respectively. Both contribute towards aging and age-related changes, specifically towards age-related diseases (ARDs) that impact the quality of life (QOL). PRP intervention has been shown to alleviate pain and disease progression in OA and reduce inflammatory markers and senescent cells (indicated in solid green lines), all of which are either precursors of aging or the effect of age-related changes. Investigations focused on the anti-aging property of PRP for age-related diseases (excluding those aimed at cosmetic applications) are yet to be explored and are indicated in the green dotted line.
Bioengineering 10 00987 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Vun, J.; Iqbal, N.; Jones, E.; Ganguly, P. Anti-Aging Potential of Platelet Rich Plasma (PRP): Evidence from Osteoarthritis (OA) and Applications in Senescence and Inflammaging. Bioengineering 2023, 10, 987. https://doi.org/10.3390/bioengineering10080987

AMA Style

Vun J, Iqbal N, Jones E, Ganguly P. Anti-Aging Potential of Platelet Rich Plasma (PRP): Evidence from Osteoarthritis (OA) and Applications in Senescence and Inflammaging. Bioengineering. 2023; 10(8):987. https://doi.org/10.3390/bioengineering10080987

Chicago/Turabian Style

Vun, James, Neelam Iqbal, Elena Jones, and Payal Ganguly. 2023. "Anti-Aging Potential of Platelet Rich Plasma (PRP): Evidence from Osteoarthritis (OA) and Applications in Senescence and Inflammaging" Bioengineering 10, no. 8: 987. https://doi.org/10.3390/bioengineering10080987

APA Style

Vun, J., Iqbal, N., Jones, E., & Ganguly, P. (2023). Anti-Aging Potential of Platelet Rich Plasma (PRP): Evidence from Osteoarthritis (OA) and Applications in Senescence and Inflammaging. Bioengineering, 10(8), 987. https://doi.org/10.3390/bioengineering10080987

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop